Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naive Patients with Compensated Cirrhosis

Lampertico, Pietro, Mauss, Stefan, Persico, Marcello, Barclay, Stephen T, Marx, Steven, Lohmann, Kristina, Bondin, Mark, Zhang, ZhenZhen, Marra, Fiona ORCID: 0000-0003-1326-1149, Belperio, Pamela S
et al (show 2 more authors) (2020) Real-World Clinical Practice Use of 8-Week Glecaprevir/Pibrentasvir in Treatment-Naive Patients with Compensated Cirrhosis. ADVANCES IN THERAPY, 37 (9). pp. 4033-4042.

Access the full-text of this item by clicking on the Open Access link.
[img] Text
Real-World Clinical Practice Use of 8-Week GlecaprevirPibrentasvir in Treatment-Naïve Patients with Compensated Cirrhosis.pdf - Published Version

Download (450kB) | Preview


<h4>Introduction</h4>More than 70 million people are estimated to be infected with hepatitis C virus globally. Glecaprevir/pibrentasvir is a widely used treatment and has recently been approved for an 8-week regimen for treatment-naïve patients with compensated cirrhosis in Europe and the USA, who would previously have received glecaprevir/pibrentasvir for 12 weeks. This label update was based on the EXPEDITION-8 study, which included 343 treatment-naïve patients with compensated cirrhosis. However, there is currently a lack of similarly large-scale real-world studies of the 8-week glecaprevir/pibrentasvir regimen in this population.<h4>Methods</h4>This summary of seven separate smaller real-world studies aims to validate the results seen in EXPEDITION-8 and provide an up-to-date real-world reference for clinicians making treatment decisions for patients with compensated cirrhosis (Child-Pugh A) who may benefit from a shorter-duration therapy with glecaprevir/pibrentasvir. The newly emerging real-world effectiveness data on treatment-naïve patients with compensated cirrhosis treated with 8 weeks of glecaprevir/pibrentasvir help to understand where further research is needed to support patients with hepatitis C virus.<h4>Results</h4>Across all seven studies, glecaprevir/pibrentasvir showed high effectiveness with an average sustained virologic response rate of 98.1%, similar to that found in a clinical trial setting (99.7%). Only one patient (0.5%) experienced virologic failure and treatment was well tolerated.<h4>Conclusion</h4>Expanding the number of patients eligible for the shortened treatment duration will potentially increase treatment initiation and completion, particularly in underserved populations, contributing to the elimination of hepatitis C virus.

Item Type: Article
Uncontrolled Keywords: Fibrosis, Hepatitis C, Infectious disease, Review, Therapeutics
Depositing User: Symplectic Admin
Date Deposited: 12 Jan 2021 10:45
Last Modified: 18 Jan 2023 23:05
DOI: 10.1007/s12325-020-01449-0
Open Access URL:
Related URLs: